Abbott Laboratories (ABT) · Aug 20, 2026 · Other events

Abbott settles 2,000 NEC claims for $670M, leaving 12,700 infants in litigation

$670M settlement — $670M resolves Gill plus ~2,000 claims; ~1,700 lawsuits involving ~12,700 infants remain

Abbott buys partial NEC litigation relief for $670 million, but 1,700 lawsuits and 12,700 infant claims remain unresolved.

The market had a clear legal-cost benchmark, but not a clean settlement consensus. Abbott faced roughly $600 million to resolve the affirmed Gill judgment alone, making the announced $670 million payment look expensive on a headline basis—but it also covers claims involving approximately 2,000 additional infants. The filing itself provides no company-wide liability estimate or published consensus against which to measure the settlement precisely.

The settlement buys meaningful but incomplete de-risking. Abbott resolves the largest specifically identified verdict and thousands of related claims for only about $70 million above the estimated cost of paying Gill alone, which is a reasonable exchange if those additional claims would otherwise have created substantial litigation exposure. The agreements cover “the Gill lawsuit as well as NEC claims asserted on behalf of approximately 2,000 additional infants for an aggregate amount of approximately $670million.”

The bigger overhang is still in place. After the deal, Abbott says roughly 1,700 lawsuits tied to approximately 12,700 individual infants remain, so this is not a global settlement or a clean end to the litigation. “Following these agreements, there are roughly 1,700 lawsuits pending in federal and state courts involving claims on behalf of approximately 12,700 individual infants.” 〔0〕

The legal signal is two-sided rather than simply negative. Abbott is accepting a substantial cash charge despite citing favorable court rulings and maintaining that the products are safe, suggesting the company values certainty and reduced distraction more than continuing the Gill appeal. But the filing does not disclose whether the settlement establishes a broader claims framework, caps future exposure, or changes the accounting treatment—leaving the ultimate cost unresolved.

Net read: partial relief, not resolution. Relative to the immediate alternative of paying the Gill judgment, the settlement is mildly constructive because it resolves thousands of additional claims at a modest incremental cost. Relative to the full litigation risk, however, the remaining claimant population is still large, so the filing merits a mixed read rather than a clean positive one.

What to watch next

Further NEC litigation and claim-screening developments

Original filing on SEC EDGAR

More Abbott Laboratories news

• Adjusted EPS and revenue edged past estimates; full-year EPS outlook raised